The restructuring events database contains factsheets with data on large-scale restructuring events reported in the principal national media and company websites in each EU Member State. This database was created in 2002.
Manufacturing (20 - 21) Manufacture of chemicals and pharmaceuticals 21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations 21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations
7,300 jobs Number of planned job losses
Announcement Date
2 February 2012
Employment effect (start)
2 February 2012
Foreseen end date
1 January 2014
Description
Anglo-Swedish pharmaceuticals firm AstraZeneca plans to cut 7,300 jobs worldwide as part of a new restructuring plan.
The firm estimates that 3,750 of the job losses will occur in its sales, general and administrative division. The number of sales and marketing regions has been reduced from five to three, and smaller countries will be clustered together for the purposes of commercial organisation. Increased use of call centres and digital channels for customer communications will provide further savings in this area.
In research and development - a division currently employing around 15,700 people - roughly 2,200 jobs will be cut. This is in part the consequence of an approach under which smaller AstraZeneca teams will collaborate with external partners, to increase flexibility.
The remaining 1,350 job losses will come from the firm's operations function, with a focus on support functions.
The UK's GMB Union has reported that 250 to 300 research and development jobs will be lost at one site in Cheshire, while further back office cuts will affect other UK locations. In Sweden, the workforce in Södertälje will be reduced by between 1100 and 1200 workers due to the closure of research facilities.
Increased competition and the expiry of patents on key AstraZeneca products have contributed to the need for cuts, according to the company.
Sources
2 February 2012: AstraZeneca website
2 February 2012: The Local
2 February 2012: BBC News Website
Citation
Eurofound (2012), AstraZeneca, Internal restructuring in World, factsheet number 73042, European Restructuring Monitor. Dublin, https://apps.eurofound.europa.eu/restructuring-events/detail/73042.
Eurofound’s ERM restructuring legislation database offers an overview of key restructuring-related regulations in the EU Member States and Norway. Its content is continuously updated to reflect any changes made by national legislators in response to, for instance, policy shifts, legal...
Can Europe still achieve its ambitions for battery manufacturing? To answer this, the article looks at data from Eurofound’s European Restructuring Monitor and explores what recent large-scale restructuring events reveal about the state of play in the EU battery sector.
This working paper offers a comprehensive methodological overview of the European Restructuring Monitor (ERM) databases. Even though the methodology has not changed over time, new categories have been added, and the way it has been used by researchers and policymakers...
This Eurofound research paper explores key trends in restructuring in recent years, highlighting the companies that announced the largest job losses and job gains in the EU. It builds on an analysis of company announcements recorded in Eurofound’s European Restructuring...
In 2023, thousands of workers in big tech lost their jobs. Meta, Amazon, Google, Apple, Microsoft and Salesforce had been considered to offer good and secure jobs up to this point. Giants of the information and communication technology (ICT) sector,...
In 2024, the automotive sector in the EU came to the fore in public and policy discussions. The focus was on the slowdown in electric vehicle (EV) sales, rising global competition, belated investments in new technologies, and the potential closure...